Bluebird 'Turns A Corner' With Lentiglobin Gene Therapy, Tests Remain

 
• By Alexandra Shimmings

Updated results of studies of its Lentiglobin gene therapy using bluebird's new manufacturing process presented at the EHA meeting are encouraging but the real test will be in the longevity of its effects and the strength of its surrogate marker.

Diagonal DNA molecule and transparent droplets, shallow focus. Biochemistry, modern medicine or genetic research related 3D rendering background
Questions remain over duration of bluebird's gene therapy

More from Clinical Trials

More from R&D